An orally bioavailable SARS-CoV-2 main protease inhibitor exhibits improved affinity and reduced sensitivity to mutations
- 13 March 2024
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 16 (738) , eadi0979
Abstract
Inhibitors of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease (M pro ) such as nirmatrelvir (NTV) and ensitrelvir (ETV) have proven effective in reducing the severity of COVID-19, but the presence of resistance-conferring mutations in sequenced viral genomes raises concerns about future drug resistance. Second-generation oral drugs that retain function against these mutants are thus urgently needed. We hypothesized that the covalent hepatitis C virus protease inhibitor boceprevir (BPV) could serve as the basis for orally bioavailable drugs that inhibit SARS-CoV-2 M pro more efficiently than existing drugs. Performing structure-guided modifications of BPV, we developed a picomolar-affinity inhibitor, ML2006a4, with antiviral activity, oral pharmacokinetics, and therapeutic efficacy similar or superior to those of NTV. A crucial feature of ML2006a4 is a derivatization of the ketoamide reactive group that improves cell permeability and oral bioavailability. Last, ML2006a4 was found to be less sensitive to several mutations that cause resistance to NTV or ETV and occur in the natural SARS-CoV-2 population. Thus, anticipatory design can preemptively address potential resistance mechanisms to expand future treatment options against coronavirus variants.Keywords
All Related Versions
This publication has 139 references indexed in Scilit:
- Innovative Randomized Phase I Study and Dosing Regimen Selection to Accelerate and Inform Pivotal COVID‐19 Trial of NirmatrelvirClinical Pharmacology & Therapeutics, 2022
- Crystal structure of SARS-CoV-2 main protease in complex with protease inhibitor PF-07321332Protein & Cell, 2021
- Covalent binders in drug discovery2019
- Comparison of antiviral resistance across acute and chronic viral infectionsAntiviral Research, 2018
- Evaluation of Enzyme Inhibitors in Drug Discovery2013
- Impact of Recovery on Fraction Unbound Using Equilibrium DialysisJournal of Pharmaceutical Sciences, 2012
- Exact and approximate solutions for the decades‐old Michaelis‐Menten equation: Progress‐curve analysis through integrated rate equationsBiochemistry and Molecular Biology Education, 2011
- Global Kinetic Explorer: A new computer program for dynamic simulation and fitting of kinetic dataAnalytical Biochemistry, 2009
- Amide and α-keto carbonyl inhibitors of thrombin based on arginine and lysine: Synthesis, stability and biological characterizationBioorganic & Medicinal Chemistry, 1995
- Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reactionBiochemical Pharmacology, 1973